Loading stock data…
BMEA
$1.14-0.01 (-1.30%)
After Hours$1.15+0.01 (+1.32%)· Last close Jun 9
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biomea Fusion, Inc. in the Healthcare sector is trading at $1.14. Wall Street consensus targets $6.83 (6 analysts), implying a +502.1% move over the next 12 months. The stock is currently near its 52-week low of $0.87, remaining 23.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +502.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.14
Potential Downside
0%
Whystock Fair Value$1.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$6.83+502.1%
Range$4.00 – $9.00
Fundamentals
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALE...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-240.13%
Volume
Today's trading volume
1.02M
Recent News
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026
Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company’s COVALENT-112 proof-of-concept study focused on safety, tolerability, and signals of beta cell function. Management said the results ma
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company’s lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator identified as Mike. The conversation centered on the scientific rationale for using menin inhibition i
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes. BMF-6
Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...